Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause

Bondi, Chiara; Ferrero, Simone; Scala, Carolina; Tafi, E.; Racca, A.; Venturini, Pier Luigi; Maggiore, Umberto Leone Roberti

doi:10.1080/17425255.2016.1218847

Cited by 10 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ospemifene is well-tolerated; increase in hot flashes is reported as the most frequent adverse effect [56]. Clinical studies suggest a significant neutral or minimum effect on the endometrium, a safe profile on the bone and cardiovascular systems and no stimulation on the breast tissue; however, further long-term studies on endometrial and breast safety are needed [57]. Indeed, Ospemifene is contraindicated in women with undiagnosed abnormal genital bleeding and known or suspected estrogen-dependent neoplasia, including breast cancer undergoing active treatment.…”

Section: Treatment Options For Menopause—related Sexual Dysfunctionsmentioning

confidence: 99%

Sexual Health in Menopause

et al. 2019

View full text Add to dashboard Cite

Sexual function worsens with advancing menopause status. The most frequently reported symptoms include low sexual desire (40-55%), poor lubrication (25-30%) and dyspareunia (12-45%), one of the complications of genitourinary syndrome of menopause (GSM). Declining levels of sex steroids (estrogens and androgens) play a major role in the impairment of sexual response; however, psychological and relational changes related with aging and an increase in metabolic and cardiovascular comorbidities should also be taken into account. Although first-line therapeutic strategies for menopause-related sexual dysfunction aim at addressing modifiable factors, many hormonal and non-hormonal, local and systemic treatment options are currently available. Treatment should be individualized, taking into account the severity of symptoms, potential adverse effects and personal preferences.

show abstract

Section: Treatment Options For Menopause—related Sexual Dysfunctionsmentioning

confidence: 99%

Sexual Health in Menopause

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Ospemifene is metabolized mainly in the liver by cytochrome P450 enzymes, primarily excreted in the bile, and eliminated in the feces [60,61]. PK parameters are therefore not affected in patients with impaired renal function.…”

Section: Pharmacokineticsmentioning

confidence: 99%

“…PK parameters are therefore not affected in patients with impaired renal function. Ospemifene may be used cautiously in patients with moderate hepatic impairment and with coadministration of ketoconazole; however, ospemifene should not be given with concomitant fluconazole [60,61].…”

Section: Pharmacokineticsmentioning

confidence: 99%

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

Archer

Simon

Portman

et al. 2019

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

Introduction: Vulvovaginal atrophy (VVA), a component of the genitourinary syndrome of menopause, is a progressive condition due to decline in estrogen leading to vaginal and vulvar epithelial changes. Accompanying symptoms of dryness, irritation, burning, dysuria, and/or dyspareunia have a negative impact on quality of life. Ospemifene is a selective estrogen receptor modulator (SERM) approved by the FDA for moderate to severe dyspareunia and vaginal dryness due to postmenopausal VVA. Areas covered: PubMed was searched from inception to March 2019 with keywords ospemifene and vulvar vaginal atrophy to review preclinical and clinical data describing the safety and efficacy of ospemifene for vaginal dryness and dyspareunia due to VVA. Covered topics include efficacy of ospemifene on vaginal cell populations, vaginal pH, and most bothersome VVA symptoms; imaging studies of vulvar and vaginal tissues; effects on sexual function; and safety of ospemifene on endometrium, cardiovascular system, and breast.

show abstract

“…11 It is metabolized by the liver, excreted in the bile, and eliminated in the feces in approximately 24 to 36 hours. 12 Being an oral medication negates the disadvantages of topical application.…”

Section: Introductionmentioning

confidence: 99%

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

Marchetti,

Taithongchai,

Robinson

2024

IJWH

View full text Add to dashboard Cite

Vulvar vaginal atrophy is a common condition affecting postmenopausal women, significantly impacting their quality of life. Fortunately, various treatment options are available, ranging from hormonal to non-hormonal therapies. Ospemifene has emerged as a promising non-hormonal alternative for managing vulvar vaginal atrophy. Its targeted approach, unique mechanism of action, favorable safety profile particularly for breast tissue, and efficacy make it a valuable option for women seeking relief from symptoms such as vaginal pain, dryness and dyspareunia and cannot receive estrogen supplementations. This is particularly the case for breast cancer survivors or women with a significant family history of estrogen-dependent cancers. Hence, tailored treatment plans, considering individual preferences and health circumstances, are essential in optimizing outcomes and improving the overall well-being of affected individuals.

show abstract

Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause

Cited by 10 publications

References 50 publications

Sexual Health in Menopause

Sexual Health in Menopause

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

Contact Info

Product

Resources

About